Drug Development Pipeline
Lenabasum (JBT-101) is an oral drug that is aimed at promoting the resolution of inflammation. It is thought to increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs.
In an earlier, smaller phase 2 trial, lenabasum was shown to reduce multiple markers of inflammation in people with CF. A larger phase 2b trial did not meet its primary objective of decreasing pulmonary exacerbations in people with cystic fibrosis.
This program is sponsored by Corbus and partially funded by the Cystic Fibrosis Foundation. It is being conducted within the Therapeutics Development Network.
Recent Lenabasum (JBT-101) Studies
Closed to Enrollment
Completed with Results
Latest News on JBT-101
March 30, 2017
Corbus Pharmaceuticals reported promising results Thursday from an early stage clinical study of a potential anti-inflammatory drug for people with cystic fibrosis.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More